/
KURA
$10.97+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$967.6M
89M shares
52-week range
$5.45 – $12.49
78% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-10.75
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $53.9M | $67.5M |
| Cost of revenue | $10.0K | $0 | $194.0K | $0 | $0 | $849.0K | $0 | $57.0K |
| Gross profit | −$10.0K | $0 | −$194.0K | $0 | $0 | −$849.0K | $53.9M | $67.4M |
| Gross margin | — | — | — | — | — | — | 100.0% | 99.9% |
| R&D | $46.8M | $47.8M | $60.4M | $84.7M | $92.8M | $115.2M | $170.0M | $251.1M |
| Operating income | −$62.9M | −$67.5M | −$91.9M | −$131.3M | −$139.9M | −$165.8M | −$193.2M | −$303.6M |
| EBITDA | −$62.9M | −$67.5M | −$88.9M | −$129.5M | −$134.9M | −$150.2M | −$169.5M | −$275.8M |
| Net income | −$60.4M | −$63.1M | −$89.6M | −$130.5M | −$135.8M | −$152.6M | −$174.0M | −$278.7M |
| Net margin | — | — | — | — | — | — | -322.9% | -412.9% |
| EPS (diluted) | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $95M | $-3.54 | $-3.85–$-2.86 | 9 |
| 2027 | $215M | $-2.65 | $-3.28–$-1.97 | 9 |
| 2028 | $298M | $-2.00 | $-3.19–$-0.35 | 10 |
| 2029 | $522M | $-0.24 | $-0.49–$-0.13 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$19.42
Price
$10.97
Implied upside
+77%
Peer comparison
Kura Oncology, Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
www.kuraoncology.com- Employees
- 260
- IPO / List date
- Aug 25, 2015
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds KURA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,582,568 | $12.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KURA yet.
